Loading stock data…
ELV
$378.07+5.15 (+1.38%)
Market ClosedLast close May 8
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Elevance Health, Inc. in the Healthcare sector is trading at $378.07. The stock is currently 11% below its 52-week high of $424.24, remaining 16.5% above its 200-day moving average. Technical signals show overbought RSI of 86 and bullish MACD crossover, explaining why ELV maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 86) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$378.07
Potential Upside
47%
Whystock Fair Value$555.76
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Buy
Mean target$388.95+2.9%
Range$331.00 – $474.00
Fundamentals
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of heal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$72.44B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.91
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
210.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.21%
Volume
Today's trading volume
1.27M
Recent News
Myomo, Inc. Q1 2026 Earnings Call Summary
Moby summary of Myomo, Inc.'s Q1 2026 earnings call
This $4 Million Warrior Met Coal Sale May Be More About Profit Taking Than Coal Prices
Warrior Met Coal supplies high-grade metallurgical coal to global steelmakers, leveraging underground mining operations in Alabama.
A Look At Elevance Health (ELV) Valuation After Q1 Beat And Raised EPS Guidance
Elevance Health (ELV) stock is back in focus after the company reported Q1 2026 results that surpassed revenue and adjusted EPS expectations and raised full year adjusted EPS guidance. See our latest analysis for Elevance Health. The Q1 earnings beat and higher guidance appear to have shifted sentiment, with a 23.83% 1 month share price return and 12.78% 90 day share price return contrasting with a 1 year total shareholder return decline of 8.32%. If Elevance Health’s recent move has you...
Is It Time To Reassess Elevance Health (ELV) After Its Recent Price Surge?
Wondering whether Elevance Health at around US$374.71 is offering good value right now? This article walks through what the current price might mean for you. The stock has seen mixed returns, with a 23.8% gain over the last 30 days but a 1-year return of an 8.3% decline and a 3-year return of a 14.4% decline, which may signal changing expectations about risk and reward. Recent news coverage has focused on Elevance Health's position within the broader US healthcare sector and how investors...
Amwell (AMWL) Q1 2026 Earnings Transcript
Ido Schoenberg: Thank you, operator. Amwell entered 2026 with one focus, consolidate our platform and deliver what payer and provider customers need most today and in the future. Technology-enabled care and AI-powered clinical programs, in particular, are now one of the most critical levers payers have.